Radioactive bullet targets tough prostate cancers

NCT ID NCT06229366

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 24 times

Summary

This study tests a radioactive drug called [Ac-225]-PSMA-62 in men with PSMA-positive prostate cancer that has spread. The goal is to find the safest and most effective dose, and to see if it can control the cancer. About 142 men with hormone-sensitive or castration-resistant prostate cancer will take part. The drug is given by IV and works by delivering radiation directly to cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BC Cancer Vancouver

    Vancouver, V5Z4E6, Canada

  • Centre Hospitalier Universite de QUEBEC

    Québec, G1J 1Z4, Canada

  • Hopital De Chicoutimi

    Saguenay, G7H 5H6, Canada

  • Jewish General Hospital

    Montreal, H3T 1E2, Canada

  • Juravinski

    Hamilton, L8V 5C2, Canada

  • McGill University

    Montreal, H4A 3J1, Canada

  • Princess Margaret Cancer Centre

    Toronto, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.